Krystal Biotech Inc (KRYS) Given Consensus Rating of “Buy” by Brokerages

Shares of Krystal Biotech Inc (NASDAQ:KRYS) have been given an average rating of “Buy” by the seven research firms that are currently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $32.60.

KRYS has been the subject of a number of research reports. Zacks Investment Research upgraded Krystal Biotech from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research note on Saturday, August 11th. Chardan Capital restated a “buy” rating and issued a $35.00 target price on shares of Krystal Biotech in a research note on Monday, August 6th. William Blair initiated coverage on Krystal Biotech in a research note on Monday, August 6th. They issued a “buy” rating for the company. HC Wainwright initiated coverage on Krystal Biotech in a research note on Monday, September 24th. They issued a “buy” rating and a $32.00 target price for the company. Finally, ValuEngine upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Friday, September 21st.

Krystal Biotech stock opened at $20.99 on Friday. Krystal Biotech has a 52-week low of $8.03 and a 52-week high of $24.89. The firm has a market cap of $297.52 million, a price-to-earnings ratio of -14.18 and a beta of -0.81.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). Equities analysts anticipate that Krystal Biotech will post -0.95 EPS for the current fiscal year.

In other Krystal Biotech news, insider Krish S. Krishnan bought 25,000 shares of the stock in a transaction dated Thursday, October 18th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 45.80% of the company’s stock.

Large investors have recently made changes to their positions in the company. P.A.W. Capital Corp acquired a new stake in shares of Krystal Biotech in the third quarter valued at $527,000. Acadian Asset Management LLC increased its position in Krystal Biotech by 552.2% in the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after purchasing an additional 10,331 shares during the period. BlackRock Inc. increased its position in Krystal Biotech by 75.4% in the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares during the period. JPMorgan Chase & Co. increased its position in Krystal Biotech by 69.0% in the third quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock worth $635,000 after purchasing an additional 14,755 shares during the period. Finally, Vanguard Group Inc. increased its position in Krystal Biotech by 13.1% in the third quarter. Vanguard Group Inc. now owns 173,478 shares of the company’s stock worth $3,050,000 after purchasing an additional 20,100 shares during the period. Institutional investors own 15.38% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

See Also: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply